cerecor-logo-final.png
Cerecor Reports Third Quarter 2020 Financial Results and Provides Business Update
November 09, 2020 16:01 ET | Cerecor Inc.
On track to complete clinical trial for CERC-002 in cytokine storm-induced COVID-19 ARDS by year end Strengthened leadership team with the appointment of Gilla Kaplan, Ph.D., to the Board of...
cerecor-logo-final.png
Cerecor Appoints Gilla Kaplan, Ph.D., to the Board of Directors
October 12, 2020 07:00 ET | Cerecor Inc.
ROCKVILLE, Md. and CHESTERBROOK, Pa., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of...
cerecor-logo-final.png
Cerecor to Present at Upcoming Investor Conferences
September 10, 2020 07:00 ET | Cerecor Inc.
ROCKVILLE, Md. and CHESTERBROOK, Pa., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of...
cerecor-logo-final.png
Cerecor Resumes Phase 1b Clinical Trial of CERC-002 for the Treatment of Severe Pediatric Onset Crohn’s Disease
August 26, 2020 07:00 ET | Cerecor Inc.
ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ : CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of...
cerecor-logo-final.png
Cerecor Announces Peer-Reviewed Publication Highlighting the Role of the Inflammatory Cytokine, LIGHT, in COVID-19 ARDS
August 13, 2020 07:00 ET | Cerecor Inc.
ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ : CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of...
cerecor-logo-final.png
Cerecor Reports Second Quarter 2020 Financial Results and Business Update
August 06, 2020 07:00 ET | Cerecor Inc.
-Generated net proceeds of $48 million from equity offering and disposition of Aytu shares to support pipeline advancement -Enrolled first patient in CERC-002 (anti-LIGHT mAb) clinical trial for the...
cerecor-logo-final.png
Cerecor to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
August 05, 2020 07:00 ET | Cerecor Inc.
ROCKVILLE, Md., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a leading biopharmaceutical company focused on the development and commercialization of treatments for rare pediatric...
cerecor-logo-final.png
Cerecor Receives Rare Pediatric Disease Designation for CERC-006 in Lymphatic Malformations
August 04, 2020 07:00 ET | Cerecor Inc.
ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a leading biopharmaceutical company in the development and commercialization of treatments for...
cerecor-logo-final.png
Cerecor Receives Orphan Drug Designation for CERC-006 in Lymphatic Malformations
August 03, 2020 07:00 ET | Cerecor Inc.
ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a leading biopharmaceutical company in the development and commercialization of treatments for...
cerecor-logo-final.png
Cerecor Announces First Patient Enrolled in Multicenter Proof-of-Concept Study Evaluating CERC-002 for COVID-19 ARDS
July 21, 2020 07:00 ET | Cerecor Inc.
ROCKVILLE, Md., July 21, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for...